# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-24-047244
Filing Date
2024-04-24
Accepted
2024-04-24 07:12:04
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | amlx-defa14a-2024-additi.htm | DEFA14A | 30467
2 | GRAPHIC | img175851018_0.jpg | GRAPHIC | 313584
3 | GRAPHIC | img175851018_1.jpg | GRAPHIC | 314611
| Complete submission text file | 0000950170-24-047244.txt |  | 896812

Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41199 | Film No.: 24866708
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)